FDA grants breakthrough designation to transcranial magnetic stimulation device for bipolar depression

FDA grants breakthrough designation to transcranial magnetic stimulation device for bipolar depression

Publication date: Mar 19, 2020

The FDA granted breakthrough device designation to the NeuroStar Advanced Therapy System for the treatment of bipolar depression, according to a press release from Neuronetics Inc. , the device’s manufacturer.

According to Tropsha, prior therapies typically have focused on treating the mania and hypomania phase of bipolar disorder, and only a few medications have been approved for the depression phase.

Since receiving FDA clearance in 2008, over 75,000 patients with depression have been treated with NeuroStar, with over 2. 5 million treatments performed.

Concepts Keywords
Antidepressant Devices manufacturer
Bipolar Depression Insurance providers
Bipolar Disorder NeuroStar depression
Bipolar Disorders Specifically bipolar disorders
Brain Major depressive disorder
Clinical Protocol Clinical protocol
Clinical Trial Psychiatry
Depression Neuroscience
Depressive Phase Branches of biology
FDA Depression
Hypomania Neurotechnology
Insurance Mood disorders
Major Depressive Disorder Psychiatric diagnosis
Mania Neurophysiology
Medicare Transcranial magnetic stimulation
Neuromodulation Major depressive disorder
Pharmacological Bipolar disorder
PhD Antidepressant
Transcranial Magnetic Stimulation
Tricare

Semantics

Type Source Name
disease MESH bipolar depression
pathway REACTOME Release
drug DRUGBANK Tilmicosin
disease MESH depression
disease MESH diagnosis
disease MESH major depressive disorder
drug DRUGBANK Spinosad

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *